Travere Therapeutics Inc (TVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2017 | 12-2016 | 09-2016 | 06-2016 | 03-2016 | |
| Sales | 33,620 | 37,327 | 33,945 | 33,311 | 29,008 |
| Cost of Goods | 709 | 1,203 | 1,573 | 1,021 | 757 |
| Gross Profit | 32,911 | 36,124 | 32,372 | 32,290 | 28,251 |
| Operating Expenses | 48,028 | 54,549 | 53,317 | 43,690 | 37,249 |
| Operating Income | -14,408 | -18,222 | -20,372 | -11,379 | -8,241 |
| Interest Expense | 132 | 4,125 | 299 | 147 | 163 |
| Other Income | 1,386 | 10,060 | -9,975 | -9,269 | 14,550 |
| Pre-tax Income | -13,154 | -12,287 | -30,646 | -20,795 | 6,146 |
| Income Tax | -2,064 | -3,684 | 6,467 | -7,392 | -5,070 |
| Net Income Continuous | -11,090 | -8,603 | -37,113 | -13,403 | 11,216 |
| Net Income | $-11,090 | $-8,603 | $-37,113 | $-13,403 | $11,216 |
| EPS Basic Total Ops | -0.29 | -0.23 | -1.00 | -0.37 | 0.31 |
| EPS Basic Continuous Ops | -0.29 | -0.23 | -1.00 | -0.37 | 0.31 |
| EPS Diluted Total Ops | -0.32 | 0.16 | -1.00 | -0.37 | -0.08 |
| EPS Diluted Continuous Ops | -0.28 | -0.18 | -1.00 | -0.37 | 0.30 |
| EBITDA(a) | $-9,837 | $-13,631 | $-15,925 | $-6,972 | $-3,798 |